Eric Hollander
Program Director/Principal Investigator · Montefiore Medical Center/Albert Einstein College of Medicine
Credentials: · · ·
History
Present/Principal Investigator · Montefiore Medical Center/Albert Einstein College of Medicine
- 1989–1990
1979–1983- 1974–1978
Research
Mapping autism risk loci using genetic linkage and chromosomal rearrangements
Nature Genetics · 2007 · 1,009 citations
Oxytocin increases retention of social cognition in autism
Biological Psychiatry · 2007 · First of 8 authors · Corresponding · 503 citations
The World Journal of Biological Psychiatry · 2008 · 479 citations
- ML
64 papers
63 papers
- DS
Deborah Stein
50 papers
- DS
35 papers
- DK
24 papers
- EA
21 papers
Franklin Schneier
20 papers
- RC
20 papers
Grants
- 2017–2023
Food and Drug Administration · R01
Contact PI · $1.5M · Albert Einstein College of Medicine
- 2005–2012
Fluoxetine in Pediatric Body Dysmorphic Disorder
Food and Drug Administration · R01
Contact PI · $1.1M · Montefiore Medical Center (Bronx, Ny)
- 2003–2009
Training in Psychopharmacology and Outcomes Research
National Institute of Mental Health · T32
Contact PI · $494.8K · Icahn School of Medicine at Mount Sinai
- 2003–2009
Greater New York Autism Research Center of Excellence
National Institute of Mental Health · U54
Contact PI · $7.3M · Icahn School of Medicine at Mount Sinai
Clinical trials
- 2021–2023
An ERP-based Mobile Intervention as an Adjunctive Treatment for OCD
Principal investigator · Unknown
BIXINK Therapeutics Co., Ltd.
- 2020–2024
CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
Principal investigator · Terminated · Phase 2
Eric Hollander
- 2019–2027
Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
Principal investigator · Recruiting · Phase 2
Montefiore Medical Center
- 2018–2022
Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome
Principal investigator · Completed · Phase 2
Eric Hollander